Blood Advances in a Different Vein

Blood Advances in a Different Vein

Research from recent issues of Blood Advances

TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML

In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...

Aggressive Imatinib Dose Escalation Shows No Improvement Over Standard Escalation in CML

For patients with newly diagnosed chronic myeloid leukemia (CML), aggressive dose escalation of imatinib failed to improve response and survival rates compared with a...

Weighing Conditioning Regimens for Patients With CML Undergoing Transplant

Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...

Eculizumab Reduces Hemolysis and Transfusion Dependency in Patients With Cold Agglutin Disease

Treatment with eculizumab, an inhibitor of the terminal complement pathway, reduced hemolysis and transfusion-dependence in patients with cold agglutin disease (CAD). However, it had...

Phlebotomy and Hydroxyurea Are Underused in Patients With Polycythemia Vera

Treatment with phlebotomy or hydroxyurea was associated with lower mortality among older patients with polycythemia vera (PV) who were considered at high thrombotic risk,...

Evaluating Twice-Yearly Denosumab for Transfusion-Dependent, Thalassemia-Induced Osteoporosis

Treatment with twice-yearly denosumab improved spinal bone mineral density (BMD) compared with placebo in patients with transfusion-dependent thalassemia (TDT)–induced osteoporosis, according to results of...

Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma

While clinical trials of the proteasome inhibitor carfilzomib for the treatment of multiple myeloma (MM) showed varying incidence rates of cardiovascular adverse events (AEs),...

Can Cytarabine Prevent Progression to Myeloid Leukemia in Children With Down Syndrome and Transient...

In pediatric patients with Down syndrome (DS) and transient myeloproliferative disorder (TMD), treatment with low-dose cytarabine lowered early mortality risk, compared with historical controls,...

Age, Anthracycline Dose, Hypertension Contribute to Higher CVD Risk in HCT Recipients

In a study published in Blood Advances, investigators reviewed data from a large cohort of patients who had undergone a hematopoietic cell transplantation (HCT)...
Advertisement

Current Issue

July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9

This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.